regeneron semaglutide pharmaceuticals announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and Regeneron's weight-loss drug combo helps

When Lower BMI Patients Might Benefit From GLP-1 Therapy People with lower BMIs may pursue GLP-1 medications for legitimate reasons beyond traditional weight loss: managing binge eating disorder, reducing visceral fat while preserving muscle with proper nutrition, improving metabolic health markers like insulin resistance or blood sugar variability, or addressing food noise and compulsive eating patterns

Clinical Pharmacology of Proton Pump Inhibitors

As a co-founder and the CEO of Artisight, he is at the forefront of fusing deep learning and IoT sensors to facilitate healthcare automation and optimization

Since semaglutide mimics the hormone GLP-1, which regulates appetite, it helps someone feel full for longer, reduces cravings for ultra-processed foods, and slows gastric emptying